Leptin pegylated super antagonist (mutant D23L/L39A/D40A/F41A) (human), (recombinant)

Recombinantr human pegylated leptin antagonist is capable of inhibiting leptin-induced proliferation of BAF/3 cells stably transfected with the long form of human leptin receptor. Its in vitro activity is 6-8 fold lower than the non-pegylated human leptin antagonist but in vivo it has profound weight gain effect (as compared to the non-pegylated human leptin antagonist), resulting mainly from increased food intake. The in vivo activity of human pegylated super leptin antagonist was compared to that of human pegylated leptin antagonist is 9-27 fold higher.

< 0.1 ng/µg of protein (<1EU/µg)

Lyophilized.

35.6 kDa

> 98.0% as determined by Gel filtration and SDS-PAGE gel.

Produced in E. coli.

P41159